Publication: Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors
Loading...
Date
2022-09-03
Authors
Hsu, Hui-Te
Yu, Chu-Chun
YUN-HSIANG LEE
Chan, Jui-Chun
CHIA-YU CHU
Journal Title
Journal ISSN
Volume Title
Publisher
SPRINGER
Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are frequently associated with dermatologic adverse events (dAEs), having great impacts on patients' health-related quality of life (HRQoL) and treatment adherence. We aimed to examine the association between various dAEs and HRQoL in patients treated with EGFR-TKI therapy.
Description
Keywords
Adverse events; Epidermal growth factor receptor-tyrosine kinase inhibitors; Lung cancer; Osimertinib; Paronychia; Quality of life